Viking Therapeutics reported a significant increase in net loss for Q3 2025, driven by robust investment in clinical development, notably for its VK2735 obesity treatment, despite achieving positive clinical trial results.

• Q3 net loss reached $90.8 million, up from $24.9 million year-over-year, reflecting a 295% increase in R&D expenses to $90 million.
• Successful Phase II results for VK2735 demonstrated significant weight loss and safety in patients with obesity, enabling advancement to Phase III trials.
• Cash reserves decreased to $715 million from $903 million since December 2024, ensuring ongoing funding for developmental activities.
• General and administrative expenses declined slightly to $8.6 million in Q3 2025, from $13.8 million in the prior year, driven by reduced legal and patent costs.
• The upcoming clinical study will explore various dosing regimens for VK2735, aiming to sustain weight loss in patients.